574 related articles for article (PubMed ID: 17441414)
1. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial.
La Grutta S; Arena A; D'Anneo WR; Gammeri E; Leonardi S; Trimarchi A; Platania D; La Rosa M
Eur Ann Allergy Clin Immunol; 2007 Feb; 39(2):40-4. PubMed ID: 17441414
[TBL] [Abstract][Full Text] [Related]
2. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
[TBL] [Abstract][Full Text] [Related]
4. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites.
Passalacqua G; Pasquali M; Ariano R; Lombardi C; Giardini A; Baiardini I; Majani G; Falagiani P; Bruno M; Canonica GW
Allergy; 2006 Jul; 61(7):849-54. PubMed ID: 16792583
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms.
Crimi N; Li Gotti F; Mangano G; Paolino G; Mastruzzo C; Vancheri C; Lisitano N; Polosa R
Ann Ital Med Int; 2004; 19(2):98-108. PubMed ID: 15317270
[TBL] [Abstract][Full Text] [Related]
7. Sublingual immunotherapy for allergic respiratory disease in elderly patients: a retrospective study.
Marogna M; Bruno ME; Massolo A; Falagiani P
Eur Ann Allergy Clin Immunol; 2008 May; 40(1):22-9. PubMed ID: 18700331
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
[TBL] [Abstract][Full Text] [Related]
9. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
10. Rush sublingual immunotherapy in Parietaria allergic patients.
D'Ambrosio FP; Ricciardi L; Isola S; Savi E; Parmiani S; Puccinelli P; Musarra A
Allergol Immunopathol (Madr); 1996; 24(4):146-51. PubMed ID: 8939269
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens.
Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF
Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.
Ozdemir C; Yazi D; Gocmen I; Yesil O; Aydogan M; Semic-Jusufagic A; Bahceciler NN; Barlan IB
Pediatr Allergy Immunol; 2007 Sep; 18(6):508-15. PubMed ID: 17680909
[TBL] [Abstract][Full Text] [Related]
13. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen.
Marogna M; Spadolini I; Massolo A; Berra D; Zanon P; Chiodini E; Canonica GW; Passalacqua G
Ann Allergy Asthma Immunol; 2009 Jan; 102(1):69-75. PubMed ID: 19205289
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and/or asthma due to grass pollen.
Agostinis F; Foglia C; Bruno ME; Falagiani P
Eur Ann Allergy Clin Immunol; 2009 Dec; 41(6):177-80. PubMed ID: 20128231
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy--preliminary data.
Ariano R; Panzani RC; Mistrello G
Eur Ann Allergy Clin Immunol; 2005 Mar; 37(3):103-8. PubMed ID: 15918297
[TBL] [Abstract][Full Text] [Related]
16. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
17. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial.
Pajno GB; Passalacqua G; Vita D; Caminiti L; Parmiani S; Barberio G
Allergy; 2004 Aug; 59(8):883-7. PubMed ID: 15230823
[TBL] [Abstract][Full Text] [Related]
18. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis.
Polosa R; Li Gotti F; Mangano G; Paolino G; Mastruzzo C; Vancheri C; Lisitano N; Crimi N
Allergy; 2004 Nov; 59(11):1224-8. PubMed ID: 15461606
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more.
Marogna M; Spadolini I; Massolo A; Canonica GW; Passalacqua G
Allergy; 2004 Nov; 59(11):1205-10. PubMed ID: 15461603
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years.
Rienzo VD; Minelli M; Musarra A; Sambugaro R; Pecora S; Canonica WG; Passalacqua G
Clin Exp Allergy; 2005 May; 35(5):560-4. PubMed ID: 15898975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
